{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:45:46Z","timestamp":1772606746176,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate awareness of and compliance in Belgium by French\u2010speaking health care professionals and patients with the isotretinoin safety recommendations regarding its teratogenic risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Survey using online questionnaires, delivered from December 2014 to March 2015 for patients, pharmacists, dermatologists, and GPs and delivered again from September 2015 to October 2015 for GPs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Questionnaires were completed by 24 dermatologists, 24 GPs, 58 pharmacists, and 33 female patients. The pregnancy prevention programme was poorly known by health care professionals (23.6%) and patients (15.2%). Health care professionals informed women of childbearing age in depth about the teratogenic risk (98.3% of pharmacists and 100.0% of GPs and dermatologists) and the importance of an effective contraceptive method (87.9% and 100.0%, respectively). Patients were less informed about the pregnancy test (25.9% and 14.6%) and the need to use a second contraceptive method (29.3% and 27.1%). The low compliance with the last 2 recommendations was due to a lack of adoption by health care professionals regarding the need for these recommendations if female patients have an effective contraceptive method and the pregnancy risk is discussed in detail with them.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The effectiveness of the pregnancy prevention programme recommendations should be reconsidered by an expert committee. Justifications should be added to effective recommendations to increase their adoption by health care professionals and patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4441","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T03:30:50Z","timestamp":1525404650000},"page":"668-673","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non\u2010compliance: Survey among French\u2010speaking health care professionals and patients in Belgium"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-3583","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Lelubre","sequence":"first","affiliation":[{"name":"Universit\u00e9 libre de Bruxelles (ULB) Facult\u00e9 de Pharmacie  Brussels Belgium"},{"name":"School of Pharmaceutical Sciences University of Geneva, University of Lausanne  Geneva Switzerland"},{"name":"Community Pharmacy, Department of Ambulatory Care and Community Medicine University of Lausanne  Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamila","family":"Hamdani","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department Federal Agency for Medicines and Health Products  Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Senterre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 libre de Bruxelles (ULB) School of Public Health, Research Center of Epidemiology, Biostatistics, and Clinical Research  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Amighi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 libre de Bruxelles (ULB) Facult\u00e9 de Pharmacie  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Peres","sequence":"additional","affiliation":[{"name":"Universit\u00e9 libre de Bruxelles (ULB) Facult\u00e9 de Pharmacie  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-9278","authenticated-orcid":false,"given":"Marie\u2010Paule","family":"Schneider","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences University of Geneva, University of Lausanne  Geneva Switzerland"},{"name":"Community Pharmacy, Department of Ambulatory Care and Community Medicine University of Lausanne  Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bugnon","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences University of Geneva, University of Lausanne  Geneva Switzerland"},{"name":"Community Pharmacy, Department of Ambulatory Care and Community Medicine University of Lausanne  Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine","family":"De Vriese","sequence":"additional","affiliation":[{"name":"Universit\u00e9 libre de Bruxelles (ULB) Facult\u00e9 de Pharmacie  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90538-X"},{"key":"e_1_2_8_3_1","unstructured":"Swissmedic.Health Professional Communication (HCP)\u2014Bon usage des r\u00e9tino\u00efdes.2017: 7\u201311. Available at:https:\/\/www.swissmedic.ch\/marktueberwachung\/00135\/00157\/03737\/index.html?lang=fr. Accessed February 24 2017."},{"key":"e_1_2_8_4_1","unstructured":"Fagg\u2010afmps.Programme de gestion des risques\u2014RMA Roaccutane.2005. Available at:http:\/\/www.fagg\u2010afmps.be\/fr\/humain\/medicaments\/medicaments\/bon_usage\/programme_de_gestion_de_risques\/rma\/r\/roaccutane\/Index.jsp. Accessed August 16 2016."},{"key":"e_1_2_8_5_1","unstructured":"EMEA.Summary of information on a referral opinion following an arbitration pursant to Article 29 of Directive 2001\/83\/EC for isotretinoin\/Lurantal\/Trivane\/Rexidal\/Scheritonin. 2013: 1. Available at:www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Isotretinoin_29\/WC500010882.pdf. Accessed August 18 2016."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09976.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/11595570-000000000-00000"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536250-000000000-00000"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3200"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.018"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.017"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.745850"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20197"},{"key":"e_1_2_8_14_1","first-page":"338","article-title":"Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations","volume":"52","author":"Boucher N","year":"2006","journal-title":"Can Fam Physician"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S149355"},{"key":"e_1_2_8_16_1","unstructured":"Questions & answers on Article 31 pharmacovigilance referral procedures. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2014\/01\/WC500159826.pdf. Accessed November 20 2017."},{"key":"e_1_2_8_17_1","unstructured":"European Medicines agency.EMA starts review of retinoid medicines\u2014effectiveness of measures for pregnancy prevention and for minimising possible risk of neuropsychiatric disorders to be evaluated.2016. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Retinoids_31\/Procedure_started\/WC500209971.pdf. Accessed May 16 2017."},{"key":"e_1_2_8_18_1","unstructured":"INAMI.Statistiques sur les m\u00e9dicaments d\u00e9livr\u00e9s en pharmacies publiques (Pharmanet). Available at:http:\/\/www.inami.fgov.be\/fr\/statistiques\/medicament\/Pages\/statistiques\u2010medicaments\u2010pharmacies\u2010pharmanet.aspx#.WEmenVzpUjI. Accessed December 9 2016."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.887678"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4441","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:17:21Z","timestamp":1695485841000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,3]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/pds.4441"],"URL":"https:\/\/doi.org\/10.1002\/pds.4441","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,3]]},"assertion":[{"value":"2017-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}